Royalty Report: Drugs, Drug Discovery, Molecular – Collection: 336355

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Molecular
  • Genome
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 336355

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee, grants to the French Licensee an exclusive license, to the Licensor patents  to make, have made, use and sell the Licensed products and/or implement the licensed process in the territory is the field.

This license is non-exclusive for the Licensed process applied to human gene therapy.

The Licensor grants an immediate, complete and free access to the Know-how.

License Property
The patents and know-how relate to processes of homologous recombination using meganucleases.
Field of Use
The Field is understood as any application of the Licensed Products and Licensed Process.

Licensor has agreed to share with a joint Licensor exploitation rights of the inventions of these patent applications and now wishes to share its rights under this technology with a industrial partner.

Licensee has as its activity the domain of genome and anti-viral therapy, the production of genomically-modified organisms, with respect to offering services to third parties, the sale of molecular biology products and reagents, the development of new therapeutic strategies, alone or in cooperation with pharmaceutical laboratories.

IPSCIO Record ID: 344487

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee, grants the French Licensee an exclusive license for the patents to make, have made, use and sell the Licensed Products and/or implement or have implemented the Licensed Process in the Territory in the Field.

The Licensor has already granted exploitation rights under the Patents to Third Parties for the production of the enzyme I-SceI, the use of the plasmid pSCM525, and, internal research.  Consequently, the term exclusive is understood for the purposes of the present agreement as the Licensor being prohibited from exploiting or having exploited or granting a license or exploitation rights under the Patents to a Third Party in the Field, other than those already granted.

License Property
The University is the owner of patents and patent applications relating to the gene of enzyme I-SceI, the expression of the enzyme I-SceI and its use.

The patent is titled Nucleotide sequence encoding the enzyme I-SceI and the uses thereof.

Field of Use
The Field is understood as any application of the Licensed Products and Licensed Process, in particular with to homologous recombination, excluding the applications for which rights have already been granted.  Homologous recombination is a type of genetic recombination in which genetic information is exchanged between two similar or identical molecules of double-stranded or single-stranded nucleic acids (usually DNA as in cellular organisms but may be also RNA in viruses). It is widely used by cells to accurately repair harmful breaks that occur on both strands of DNA, known as double-strand breaks (DSB).

IPSCIO Record ID: 336350

License Grant
The French Institute grants to the French Licensee an exclusive license under the Agreement Patents to make, have made, use and sell the Licensed Products and/or implement or have implemented the Licensed Process in the Territory in the Field.

The amendment 2 updates the field of use.

License Property
Licensor is owner of patents and patent applications relating to a method of homologous recombination.

The patent is titled “procédé de remplacement spécifique d’une copie d’un gène present dans le genome receveur par l’intégration d’un gène different de celui où se fait l’intégration”

Field of Use
The Field of this Agreement concerns the field of homologous recombination applied to any genes excluding cytokines, hormones and human growth factors.

The Amendment 2 clarifies  
This exclusion does not apply in either of the following cases
–  As part of the creation of test animals used as a research and medication screening and validation tool;
–  As part of use combined with the PGN patents on the one hand and I-SceI and/or I-Spom I and/or Mulligan on the other hand, excluding applications for Erythropoietin (EPO).

Amendment 3 clarifies
The Field covers the field of homologous recombination applied to all genes other than those that code for Erythropoietin (EPO).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.